Literature DB >> 8021438

Placebo-controlled efficacy of antidepressants in continuation treatment.

S A Montgomery1, A Roberts, A G Patel.   

Abstract

All episodes of depression require treatment after symptomatic response of the acute episode in order to consolidate response. If treatment is discontinued early, 30% to 50% of patients will suffer a relapse of the inadequately treated episode. Placebo-controlled studies with a variety of antidepressants, old and new, have provided compelling evidence of the efficacy of anti-depressants on relapse prevention. A recent study of citalopram has also shown the need for long-term treatment with anti-depressants in patients whose acute episode of depression appeared to respond to placebo since their response was not maintained.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8021438     DOI: 10.1097/00004850-199403001-00008

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  5 in total

Review 1.  Treatment of recurrent depression: an alternate viewpoint.

Authors:  Michael E Thase
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  How many good antidepressant medications have we missed?

Authors:  Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2004-07       Impact factor: 6.186

3.  Do antidepressants really work?

Authors:  Pierre Blier
Journal:  J Psychiatry Neurosci       Date:  2008-03       Impact factor: 6.186

4.  Do Nonsuicidal Severely Depressed Individuals with Diabetes Profit from Internet-Based Guided Self-Help? Secondary Analyses of a Pragmatic Randomized Trial.

Authors:  Sandra Schlicker; Kiona K Weisel; Claudia Buntrock; Matthias Berking; Stephanie Nobis; Dirk Lehr; Harald Baumeister; Frank J Snoek; Heleen Riper; David D Ebert
Journal:  J Diabetes Res       Date:  2019-05-14       Impact factor: 4.011

5.  The self-reported Montgomery-Asberg Depression Rating Scale is a useful evaluative tool in Major Depressive Disorder.

Authors:  Bruno Fantino; Nicholas Moore
Journal:  BMC Psychiatry       Date:  2009-05-27       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.